CPRX..$1.97..Catalyst Pharmaceutical jumps on CPP-115 news
Catalyst Pharmaceutical (CPRX +21.2%) soars after announcing that Epilepsia has accepted a paper demonstrating proof of concept of the GABA aminotransferase inhibitor CP-115 in IS. The paper's author is a principal investigator in the CP-115 preclinical study (rodents). CPRX also says it expects to initiate a Phase 1 study in H1 2014 to evaluate safety and tolerability. (PR)